BASIC AND CLINICAL STUDIES ON CEFOTIAM HEXETIL, A NEW ORAL CEPHALOSPORIN ANTIBIOTIC, IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement6; pp. 655 - 666
• Main Authors: IWAI, SHIGETOMI, FUJII, MASASHI, SATO, TAKESHI, MATSUSHITA, KANEAKI, KUNIMATSU, MASAHIKO, HORIKAWA, AKIRA, FURUHATA, HISASHI, NISHIKAWA, TOORU, KATO, KOUMEI, CHISHIMA, YOSHIAKI, SATO, IZUMI, SAKAI, HIROKO, SAKABE, TAKASHI, ANRAKU, REI, KAJIWARA, MASAMU, TOMINAGA, MIKIHIRO, OOSAWA, TAKASHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• Subjects: Cefotiam hexetil
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement6_655

We performed basic and clinical studies on cefotiam hexetil (CTM-HE), a new oral cephalosporin, and obtained the following results. Antibacterial activity of CTM-HE against clinical isolates was compared with those of ampicillin (ABPC), cephalexin (CEX), cefaclor (CCL), lincomycin (LCM), clindamycin (CLDM), minocycline (MINO), norfloxacin (NFLX) and ofloxacin (OFLX). MICS of cefotiam hexetil were determined against clinical isolates of coagulase-positive and-negative staphylococci, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae and Bacteroides fragilis. The drug showed good activity against staphylococci, but less so against E. faecalis. It also demonstrated excellent activity against E. coli, good activity against K. pneumoniae, but less against B. fragilis. In the clinical study, cefotiam hexetil was administered to 20 patients with infections mainly of the skin and soft tissue. Clinical response was good enough in 16 cases (80.0%) and poor in 4. No serious side effects were noted except one case of diarrhea.